+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peptide Antibiotics Market Analysis by Disease, by Product Type, by Distribution Channel, by Route of Administration, and by Region - Global Forecast to 2029

  • PDF Icon

    Report

  • 200 Pages
  • September 2022
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5653911
The peptide antibiotics market size is estimated to be USD 6,210 million in 2021 and is expected to witness a CAGR of 6.45% during the forecast period 2022-2029. The increasing instances of antibiotic resistance, rising need for peptide antibiotics in hospitals and clinics, increasing the number of product launches and approvals, and a rise in the incidence of illnesses such as bloodstream infections, hospital-acquired infections, and bacterial skin infections are some of the primary market drivers. However, using peptide antibiotics over an extended period of time has a lot of negative side effects are expected to restrain the market growth.

By Disease

Based on Disease, the market is segregated into blood stream infections, skin infections, HABP/VABP, and others. In 2021, the skin infections segment held the highest market share owing to increasing occurrence of bacterial skin illnesses such as carcuncles, impetigo, cellulitis, furuncles, and others, as well as widespread product availability.

By Product Type

On the basis of product type, the market is bifurcated into non-ribosomal synthesized peptide antibiotics and ribosomal synthesized peptide antibiotics. In 2021, the non-ribosomal synthesized peptide antibiotics segment held the highest market share due to the increasing accessibility of antibiotics made through a non-ribosomal synthesis, and rising demand for antibiotics made without ribosomes.

By Distribution Channel

Based on distribution channel, the market is segregated into specialty clinics, hospitals, homecare, and others. In 2021, the hospitals segment held the highest market share owing to Increasing bacterial skin infections and ocular infections are causing doctors to prescribe more peptide antibiotics, and increasing rates of hospital-acquired infections, bloodstream infections, and extended hospital stay.

By Route of Administration

Based on route of administration, the market is categorized into topical, oral, parenteral, and others. In 2021, the parenteral segment held the highest market share due to the availability of a large number of peptide antibiotics in injectable form, efficiency, and better bioavailability from injectable peptide antibiotics.

Regional Markets

In 2021, North America had the greatest share of the market due to the increased antibiotic demand in this region, as well as an expansion in R&D activity in the region, the existence of a vast number of market participants, and strategic actions made by important stakeholders. However, the Asia-Pacific region is predicted to grow at the fastest rate during the projection period owing to the increasing elderly population and rise in patient health consciousness, and a rise in the occurrence of different infectious illnesses.

Competitor Insights

Some of the key players operating in the peptide antibiotics market are Abbott (US), AbbVie Inc (US), Allergan Plc )Ireland), Dr. Reddy’s Laboratories Ltd (India), Fresenius Kabi AG (Germany), GSK (UK), HENGRUI (USA), Lilly (US), Merck (US), Novartis AG (Switzerland), Pfizer (US), Sandoz International GmbH (Germany), Sanofi (France), and Teva Pharmaceutical Industries Ltd. (Israel).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including disease, product type, distribution channel and route of administration from 2022-2029.

Segmentation: Peptide Antibiotics Market Analysis Report 2021-2029

Disease (Revenue, USD Million)

  • Blood Stream Infections
  • Skin Infections
  • HABP/VABP
  • Others

Product Type (Revenue, USD Million)

  • Non-ribosomal Synthesized Peptide Antibiotics
  • Ribosomal Synthesized Peptide Antibiotics

Distribution Channel (Revenue, USD Million)

  • Specialty Clinics
  • Hospitals
  • Homecare
  • Others

By Route of Administration (Revenue, USD Million)

  • Topical
  • Oral
  • Parenteral
  • Others

By Region (Revenue, USD Million)

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
1.4.1. Research Models
1.4.1.1. Bottom-up Approach
1.4.1.2. Top-down Approach
1.4.1.3. Data Triangulation
1.4.2. Data Procurement
1.4.2.1. Internal Database
1.4.2.2. Secondary Research
1.4.2.3. Purchased Database
1.4.2.4. Primary Research
1.4.3. Data Analysis
1.4.3.1. Data Validation
1.4.3.2. Market Size Estimation
1.4.3.3. Market Forecast Model
1.4.4. Quality Assessment
2. Introduction: Peptide Antibiotics
3. Executive Summary
3.1. Global Market Scenario
3.2. Segment Market Scenario
3.3. Geographic Market Scenario
3.4. COVID-19 Impact
3.5. Competitive Landscape
4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.1.5. Driver 5
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.2.4. Restraint 4
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.3.4. Opportunity 4
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.4.4. Trend 4
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3
4.5.4. Challenge 4
5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. Value Chain Analysis
5.4. SWOT Analysis
5.5. Benchmark
6. COVID-19 Impact Analysis: Peptide Antibiotics Market
6.1. COVID-19: Overview
6.2. COVID-19 Impact on the Global Market
6.3. COVID-19 Impact on the Regional Markets
7. Market Analysis by Disease
7.1. Blood Stream Infections
7.1.1. Blood Stream Infections Market Forecast, 2021-2029 (USD Million)
7.2. Skin Infections
7.2.1. Skin Infections Market Forecast, 2021-2029 (USD Million)
7.3. HABP/VABP
7.3.1. HABP/VABP Market Forecast, 2021-2029 (USD Million)
7.4. Others
7.4.1. Others Market Forecast, 2021-2029 (USD Million)
8. Market Analysis by Product Type
8.1. Non-ribosomal Synthesized Peptide Antibiotics
8.1.1. Non-ribosomal Synthesized Peptide Antibiotics Market Forecast, 2021-2029 (USD Million)
8.2. Ribosomal Synthesized Peptide Antibiotics
8.2.1. Ribosomal Synthesized Peptide Antibiotics Market Forecast, 2021-2029 (USD Million)
9. Market Analysis by Distribution Channel
9.1. Specialty Clinics
9.1.1. Specialty Clinics Market Forecast, 2021-2029 (USD Million)
9.2. Hospitals
9.2.1. Hospitals Market Forecast, 2021-2029 (USD Million)
9.3. Homecare
9.3.1. Homecare Market Forecast, 2021-2029 (USD Million)
9.4. Others
9.4.1. Others Market Forecast, 2021-2029 (USD Million)
10. Market Analysis by Route of Administration
10.1. Topical
10.1.1. Topical Market Forecast, 2021-2029 (USD Million)
10.2. Oral
10.2.1. Oral Market Forecast, 2021-2029 (USD Million)
10.3. Parenteral
10.3.1. Parenteral Market Forecast, 2021-2029 (USD Million)
10.4. Others
10.4.1. Others Market Forecast, 2021-2029 (USD Million)
11. Regional Market Analysis
11.1. Regional Market Trends
11.2. Regional Market: Comparative Analysis
12. North America Peptide Antibiotics Market
12.1. North America Peptide Antibiotics Market
12.1.1. North America Market Size and Forecast, 2021-2029 (USD Million)
12.1.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
12.1.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
12.1.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
12.1.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
12.2. U. S. Peptide Antibiotics Market
12.2.1. U. S. Market Size and Forecast, 2021-2029 (USD Million)
12.2.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
12.2.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
12.2.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
12.2.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
12.3. Canada Peptide Antibiotics Market
12.3.1. Canada Market Size and Forecast, 2021-2029 (USD Million)
12.3.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
12.3.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
12.3.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
12.3.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
13. Europe Peptide Antibiotics Market
13.1. Europe Peptide Antibiotics Market
13.1.1. Europe Market Size and Forecast, 2021-2029 (USD Million)
13.1.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
13.1.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
13.1.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
13.1.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
13.2. Germany Peptide Antibiotics Market
13.2.1. Germany Market Size and Forecast, 2021-2029 (USD Million)
13.2.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
13.2.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
13.2.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
13.2.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
13.3. UK Peptide Antibiotics Market
13.3.1. UK Market Size and Forecast, 2021-2029 (USD Million)
13.3.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
13.3.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
13.3.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
13.3.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
13.4. France Peptide Antibiotics Market
13.4.1. France Market Size and Forecast, 2021-2029 (USD Million)
13.4.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
13.4.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
13.4.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
13.4.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
13.5. Spain Peptide Antibiotics Market
13.5.1. Spain Market Size and Forecast, 2021-2029 (USD Million)
13.5.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
13.5.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
13.5.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
13.5.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
13.6. Italy Peptide Antibiotics Market
13.6.1. Italy Market Size and Forecast, 2021-2029 (USD Million)
13.6.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
13.6.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
13.6.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
13.6.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
13.7. Rest of Europe Peptide Antibiotics Market
13.7.1. Rest of Europe Market Size and Forecast, 2021-2029 (USD Million)
13.7.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
13.7.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
13.7.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
13.7.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
14. Asia Pacific Peptide Antibiotics Market
14.1. Asia Pacific Peptide Antibiotics Market
14.1.1. Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
14.1.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
14.1.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
14.1.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
14.1.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
14.2. Japan Peptide Antibiotics Market
14.2.1. Japan Market Size and Forecast, 2021-2029 (USD Million)
14.2.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
14.2.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
14.2.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
14.2.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
14.3. China Peptide Antibiotics Market
14.3.1. China Market Size and Forecast, 2021-2029 (USD Million)
14.3.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
14.3.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
14.3.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
14.3.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
14.4. India Peptide Antibiotics Market
14.4.1. India Market Size and Forecast, 2021-2029 (USD Million)
14.4.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
14.4.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
14.4.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
14.4.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
14.5. South Korea Peptide Antibiotics Market
14.5.1. South Korea Market Size and Forecast, 2021-2029 (USD Million)
14.5.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
14.5.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
14.5.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
14.5.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
14.6. Australia Peptide Antibiotics Market
14.6.1. Australia Market Size and Forecast, 2021-2029 (USD Million)
14.6.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
14.6.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
14.6.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
14.6.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
14.7. Rest of Asia Pacific Peptide Antibiotics Market
14.7.1. Rest of Asia Pacific Market Size and Forecast, 2021-2029 (USD Million)
14.7.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
14.7.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
14.7.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
14.7.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
15. Latin America Peptide Antibiotics Market
15.1. Latin America Peptide Antibiotics Market
15.1.1. Latin America Market Size and Forecast, 2021-2029 (USD Million)
15.1.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
15.1.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
15.1.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
15.1.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
15.2. Brazil Peptide Antibiotics Market
15.2.1. Brazil Market Size and Forecast, 2021-2029 (USD Million)
15.2.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
15.2.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
15.2.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
15.2.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
15.3. Mexico Peptide Antibiotics Market
15.3.1. Mexico Market Size and Forecast, 2021-2029 (USD Million)
15.3.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
15.3.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
15.3.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
15.3.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
15.4. Argentina Peptide Antibiotics Market
15.4.1. Argentina Market Size and Forecast, 2021-2029 (USD Million)
15.4.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
15.4.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
15.4.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
15.4.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
15.5. Rest of Latin America Peptide Antibiotics Market
15.5.1. Rest of Latin America Market Size and Forecast, 2021-2029 (USD Million)
15.5.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
15.5.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
15.5.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
15.5.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
16. MEA Peptide Antibiotics Market
16.1. MEA Peptide Antibiotics Market
16.1.1. MEA Market Size and Forecast, 2021-2029 (USD Million)
16.1.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
16.1.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
16.1.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
16.1.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
16.2. GCC Peptide Antibiotics Market
16.2.1. GCC Market Size and Forecast, 2021-2029 (USD Million)
16.2.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
16.2.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
16.2.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
16.2.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
16.3. South Africa Peptide Antibiotics Market
16.3.1. South Africa Market Size and Forecast, 2021-2029 (USD Million)
16.3.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
16.3.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
16.3.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
16.3.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
16.4. Rest of MEA Peptide Antibiotics Market
16.4.1. Rest of MEA Market Size and Forecast, 2021-2029 (USD Million)
16.4.1.1. Market Size and Forecast by Disease, 2021-2029 (USD Million)
16.4.1.2. Market Size and Forecast by Product Type, 2021-2029 (USD Million)
16.4.1.3. Market Size and Forecast by Distribution Channel, 2021-2029 (USD Million)
16.4.1.4. Market Size and Forecast by Route of Administration, 2021-2029 (USD Million)
17. Competitor Analysis
17.1. Market Share Analysis, 2021 & 2029
17.2. Competitive Mapping
17.3. Key Players Market Place Analysis
17.4. Major Recent Developments
18. Company Profiles
18.1. Abbott (US)
18.1.1. Company Snapshot
18.1.2. Company Overview
18.1.3. Financials
18.1.4. Product Benchmarking
18.1.5. Recent Developments
18.2. AbbVie Inc (US)
18.2.1. Company Snapshot
18.2.2. Company Overview
18.2.3. Financials
18.2.4. Product Benchmarking
18.2.5. Recent Developments
18.3. Allergan Plc )Ireland)
18.3.1. Company Snapshot
18.3.2. Company Overview
18.3.3. Financials
18.3.4. Product Benchmarking
18.3.5. Recent Developments
18.4. Dr. Reddy’s Laboratories Ltd (India)
18.4.1. Company Snapshot
18.4.2. Company Overview
18.4.3. Financials
18.4.4. Product Benchmarking
18.4.5. Recent Developments
18.5. Fresenius Kabi AG (Germany)
18.5.1. Company Snapshot
18.5.2. Company Overview
18.5.3. Financials
18.5.4. Product Benchmarking
18.5.5. Recent Developments
18.6. GSK (UK)
18.6.1. Company Snapshot
18.6.2. Company Overview
18.6.3. Financials
18.6.4. Product Benchmarking
18.6.5. Recent Developments
18.7. HENGRUI (USA)
18.7.1. Company Snapshot
18.7.2. Company Overview
18.7.3. Financials
18.7.4. Product Benchmarking
18.7.5. Recent Developments
18.8. Lilly (US)
18.8.1. Company Snapshot
18.8.2. Company Overview
18.8.3. Financials
18.8.4. Product Benchmarking
18.8.5. Recent Developments
18.9. Merck (US)
18.9.1. Company Snapshot
18.9.2. Company Overview
18.9.3. Financials
18.9.4. Product Benchmarking
18.9.5. Recent Developments
18.10. Novartis AG (Switzerland)
18.10.1. Company Snapshot
18.10.2. Company Overview
18.10.3. Financials
18.10.4. Product Benchmarking
18.10.5. Recent Developments
18.11. Pfizer (US)
18.11.1. Company Snapshot
18.11.2. Company Overview
18.11.3. Financials
18.11.4. Product Benchmarking
18.11.5. Recent Developments
18.12. Sandoz International GmbH (Germany)
18.12.1. Company Snapshot
18.12.2. Company Overview
18.12.3. Financials
18.12.4. Product Benchmarking
18.12.5. Recent Developments
18.13. Sanofi (France)
18.13.1. Company Snapshot
18.13.2. Company Overview
18.13.3. Financials
18.13.4. Product Benchmarking
18.13.5. Recent Developments
18.14. Teva Pharmaceutical Industries Ltd. (Israel)
18.14.1. Company Snapshot
18.14.2. Company Overview
18.14.3. Financials
18.14.4. Product Benchmarking
18.14.5. Recent Developments
18.15. Company 15
18.15.1. Company Snapshot
18.15.2. Company Overview
18.15.3. Financials
18.15.4. Product Benchmarking
18.15.5. Recent Developments
18.16. Others Prominent Players
19. Conclusion20. Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott (US)
  • AbbVie Inc (US)
  • Allergan Plc )Ireland
  • Dr. Reddy’s Laboratories Ltd (India)
  • Fresenius Kabi AG (Germany)
  • GSK (UK)
  • HENGRUI (USA)
  • Lilly (US)
  • Merck (US)
  • Novartis AG (Switzerland)
  • Pfizer (US)
  • Sandoz International GmbH (Germany)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Ltd. (Israel).